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Patients  with  chronic  myeloid  leukemia  develop  resistance  to  both  ﬁrst-generation  and  second-
generation  tyrosine  kinase  inhibitors  (TKIs)  as  a result  of  mutations  in the  kinase  domain  (KD)  of
BCR-ABL1.  A  wide  range  of  BCR-ABL1  KD  mutations  that  confer  resistance  to  TKIs  have  been  identiﬁed,
and the  T315I  mutant  has  proven  particularly  difﬁcult  to  target.  This  review  summarizes  the  prevalence,
impact,  and  prognostic  implications  of  BCR-ABL1  KD mutations  in patients  with  chronic  myeloid  leukemia
who are  treated  with  current  TKIs  and  provides  an  overview  of  recent  treatment  guidelines  and  futureCR-ABL1
inase domain
yrosine kinase inhibitors
hiladelphia chromosome
trends  for the  detection  of  mutations.
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. Introduction
Chronic myeloid leukemia (CML) is characterized by the pres-
nce of the Philadelphia chromosome (Ph+), which contains the
ncogenic BCR-ABL1 fusion gene resulting from a translocation
etween chromosomes 9 and 22 [1,2]. This disease accounts for
5% of adult leukemias, with an estimated 5920 new cases and 610
eaths due to this disease in the United States (US) in 2013 [3].
Five BCR-ABL1 tyrosine kinase inhibitors (TKIs)—imatinib [4],
asatinib [5], nilotinib [6], bosutinib [7], and ponatinib [8]—have
een approved in the US for the treatment of CML  patients.
matinib, dasatinib, and nilotinib are indicated for both newly diag-
osed patients and patients with relapsed or refractory disease,
hereas bosutinib and ponatinib are indicated for patients with
esistance or intolerance to prior TKIs. Recently, omacetaxine, a
rotein synthesis inhibitor, has been approved in the US for CML
atients resistant to and/or intolerant of two or more BCR-ABL1
KIs [9]. Although BCR-ABL1 TKIs have not been formally com-
ared with omacetaxine, TKIs are generally the preferred option
3]. Interferon- alone is no longer considered as initial therapy
or newly diagnosed CML  patients [3,10], although it can be used
uring pregnancy [10–12], and clinical trials evaluating its use in
ombination with TKIs are ongoing [13]. It can also be considered
s an option for patients who are unable to tolerate TKI therapy [3].
ntil recently, imatinib was the only ﬁrst-line option; therefore, the
ajority of newly diagnosed CML  patients living today have been
reated with imatinib. Now that three TKIs (imatinib, dasatinib, and
ilotinib) are approved ﬁrst-line options, the choice of initial agent
epends on many different factors [3,10]. Second-generation TKIs
re more potent and are associated with lower rates of blastic trans-
ormation on study treatment [14,15], along with a lower level of
utation vulnerability than imatinib [16]. On the other hand, there
s longer experience with imatinib than with second-generation
KIs with respect to side effects and safety [14,15,17].
Despite high response rates to BCR-ABL1 TKIs, primary resis-
ance and secondary resistance have been observed: primary
intrinsic) resistance is deﬁned as lack of initial response, and
econdary (acquired) resistance (relapse) is deﬁned as loss of an
stablished response during TKI treatment [18]. Resistance has
een deﬁned using the European LeukemiaNet (ELN) criteria for
ailure of ﬁrst-line TKI therapy: less than a complete hemato-
ogic response (CHR) and/or no cytogenetic response (CyR; deﬁned
s Ph+ bone marrow metaphases >95%) at 3 months, BCR-ABL1
ranscript levels above 10% and/or less than a partial CyR (PCyR;
eﬁned as ≤35% Ph+ metaphases) at 6 months, BCR-ABL1 tran-
cript levels above 1% and/or less than a complete CyR (CCyR;
eﬁned as no Ph+ metaphases) at 12 months, or loss of a CHR
r CCyR or conﬁrmed loss of MMR,  mutations, or clonal chromo-
ome abnormalities in Ph− cells at any subsequent time during
herapy [10,19]. According to the National Comprehensive Cancer
etwork (NCCN) guidelines, resistance is deﬁned as the detection
f BCR-ABL1/ABL1 transcript levels above 10% on the International
cale or failure to achieve PCyR at 3 months, or failure to achieve . . . .  .  .  .  .  .  . . . .  .  .  .  .  .  . . .  . .  .  .  .  . . . . . .  .  .  .  . . . . . . .  .  .  . . . .  . .  .  . .  . .  .  .  . .  .  .  .  .  . . . .  . .  .  .  . . 18
CCyR at 12 months or 18 months [3]. Several mechanisms have
been associated with resistance, including BCR-ABL1-dependent
and BCR-ABL1-independent mechanisms [20]. BCR-ABL1 kinase
domain (KD) mutations and BCR-ABL1 genomic ampliﬁcation are
the best-characterized mechanisms conferring resistance to TKI
therapy [21]. Numerous mutations have been identiﬁed (Fig. 1)
[22]. Mutation analysis is usually performed after patients expe-
rience TKI treatment resistance; the results of mutation analysis
may  guide the selection of subsequent TKIs [3,10,19,22]. Currently,
few mutations are known to confer clinical resistance to niloti-
nib (Y253H, E255K/V, and F359V/C/I) [23,24] or dasatinib (V299L,
T315A, F317L/I/V/C) [24–27] or both (T315I). Patients already har-
boring mutations have higher likelihood of developing additional
mutations [21,24], leading to the appearance of multiple mutations,
which can be associated with poor prognosis [26,28,29]. Compound
mutations are deﬁned as two or more codon changes in the same
BCR-ABL1 mRNA molecule, and thereby within a single clone; poly-
clonal mutations are deﬁned as two  or more codon changes across
different BCR-ABL1 mRNA molecules, and therefore presumably
belonging to different mutant clones [21]. As patients are sequen-
tially treated with different TKIs, new mutations may emerge [24].
In a series of 17 imatinib-resistant CML  patients treated sequen-
tially with imatinib and dasatinib at UCLA, 30% had compound
mutations (detected by subcloning and sequencing) at the time of
relapse with dasatinib that were not detected prior to dasatinib
treatment [26]. Based on an analysis conducted in 47 CML  patients
on TKI therapy, the majority (70%) of double mutations detected by
direct sequencing represent compound mutations.
BCR-ABL1 KD mutation analysis can be conducted by direct
Sanger sequencing, which has been largely used to-date [10,22]. In
addition, newer technologies with greater sensitivity are available,
but most of them are limited by their speciﬁcity for a deﬁnite and
limited spectrum of mutations. Next-generation sequencing (NGS)
is the only exception.
2. Emergence of BCR-ABL1 KD mutations with current TKIs
2.1. Resistance and mutations with ﬁrst-line imatinib
While treatment with ﬁrst-line imatinib is associated with high
hematologic response rates, a proportion of patients may fail to
experience cytogenetic responses (primary resistance) [18]. Across
the historical trials of imatinib, approximately 65–90% of chronic-
phase (CP) CML  patients experience CCyR at/by 12–24 months
(Table 1) [14,16,30–38].
Resistance to imatinib treatment can also occur after patients
have achieved an initial response (secondary resistance). Based on
the 6-year update of the IRIS trial, the discontinuation rate was
34% and the estimated cumulative annual event rate, including
loss of CHR, loss of MCyR, progression to accelerated phase (AP)
or blast phase (BP), or death during treatment, was  18%, of which
an estimated 7% account for patients who progressed to AP/BP [17].
12 S. Soverini et al. / Leukemia Research 38 (2014) 10– 20
Fig. 1. Map  of mutations in the BCR-ABL1 KD identiﬁed in clinical samples from patients resistant to imatinib. Key structural motifs within the KD are indicated: P-loop
indicates phosphate binding loop, SH2 contact and SH3 contact represent the contact regions with SH2 and SH3 domain-containing proteins, and A-loop indicates the
activation loop. K247R and Y320C are in italics because they have been reported to be single-nucleotide polymorphisms. Numbering of residues is according to ABL1a
isoform.
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mong the 456 patients who achieved CCyR, the estimated annual
ates of treatment failure were 5% in the ﬁrst year, 2% in the sec-
nd year, 1% in the third year, and 0.3% in the fourth year after
chieving that response. The corresponding annual rates of AP/BP
rogression were 2%, 0.7%, 0.3%, and 0%, respectively. The event-
ree survival (EFS) rate was substantially worse in patients with
o CyR (59%) and minimal/minor CyR (58%), compared with those
ith PCyR (85%) and CCyR (91%).
Findings from several studies indicate that BCR-ABL1 muta-
ions are detected with a frequency ranging from 12% to 63% in
ML  patients who experienced imatinib resistance (Table 2). The
ost common mutations with imatinib were T315I, G250E, M244V,
351T, and E255K/V (Table 2). In most studies, more patients
ith secondary resistance developed mutations during imatinib
able 1
CyR rates from clinical trials of imatinib in the ﬁrst-line setting.
Trial Daily i
IRIS [30] 400 m
MD  Anderson Cancer Center [31] 800 m
Hammersmith Hospital [32] 400 m
TIDEL-I  [33] 600 m
RIGHT  [34] 800 m
TOPS [35] 400 m
800 m
SPIRIT  [36] 400 m
600  m
GIMEMA CML  WP  trials (CML/021, CML/022, CML/023) [37] 400 m
800  m
German CML  study IV [38] 400 m
800 m
ENESTnd [16] 400 m
DASISION [14] 400 m
CyR, complete cytogenetic response; IRIS, International Randomized Study of Interfero
ationale and Insight for Gleevec High-dose Therapy; TOPS, Tyrosine kinase Inhibitor OP
ML  WP,  Italian Group for Hematological Malignancies of the Adult CML  Working Party; E
atients; DASISION, DASatinib versus Imatinib Study In treatment-Naive CML  patients.
a Estimated response rate.
b 83% of evaluated patients.
c Conﬁrmed CCyR was  74%.main mutation analysis in chronic myeloid leukemia patients treated with tyrosine
iaNet, Soverini S, et al., Blood, volume 118, number 5, copyright 2011; permission
treatment than those with primary resistance (Table 2). Between
21% and 48% of cases of primary resistance and 10–68% of cases
of secondary resistance were associated with mutations (Table 2)
[39–49].
2.2. Resistance and mutations with second-line dasatinib or
nilotinib
Thirteen percent of CP-CML patients treated with dasatinib
100 mg  once daily, the approved dose, discontinued the CA180-
034 trial as second-line treatment because of disease progression,
at a minimum follow-up of 24 months [50]. In this trial, disease
progression was  deﬁned as conﬁrmed AP or BP, loss of a previ-
ous CHR or MCyR, ≥30% increase in Ph+ metaphases, increasing
matinib dose N CCyR rate
g  553 74% at 18 months
g  114 90% by 18 monthsa
g  224 65% by 19.5 months
g  103 88% by 12 months
90% by 24 months
g  115 61% at 18 monthsb
g  157 66% by 12 months
g  319 70% by 12 months
g  159 58% at 12 months
g  160 65% at 12 months
g  423 78% at 12 months
g  136 77% at 18 months
g  303 66% by 18 months
74% by 24 months
g  311 75% by 18 months
82% by 24 months
g  283 77% by 24 months
g  260 82% by 24 monthsc
n and STI571; TIDEL-I, Therapeutic Intensiﬁcation in DE-novo Leukaemia; RIGHT,
timization and Selectivity; SPIRIT, STI571 ProspectIve RandomIzed Trial; GIMEMA
NESTnd, Evaluating Nilotinib Efﬁcacy and Safety in clinical Trials—newly diagnosed
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Table 2
Summary of mutation analysis conducted at imatinib failure in a series of studies of imatinib with or without previous interferon-, in which at least 50 patients were
analyzed.
Trial Frequency of
BCR-ABL1 mutations
(n/N)a
Frequency of
mutations among
patients with
mutationsb
CML phase Primary vs
secondary resistance
(n/N)c
Method used
GIMEMA CML WP [39] 43% (127/297d) E255K/V (17%)
Y253F/H (13%)
T315I (12%)
M351T (11%)
F359V/I (11%)
M244V (10%)
G250E (10%)
CP; LBC/Ph+ALL;
MBC; AP
30% (45/152) vs 57%
(82/145)
D-HPLC and direct
sequencing
MD  Anderson Cancer Center [40] 54% (61/112e) G250E (20%)
T315I (16%)
F317L (11%)
E355G (8%)
CP; AP; BP NA Direct sequencing
Argentinean  study [41] 23% (36/154f) G250E (17%)
M351T (14%)
T315I (11%)
Y253H (11%)
E255V (8%)
E255K (8%)
CP; AP; BP 21% (16/77) vs 34%
(20/59)
Direct sequencing
Chinese  study [42] 58% (74/127) M244V (16%)
Y253H (14%)
G250E (11%)
T315I (10%)
F359C/V/I (10%)
CP; AP; BP 48% (31/64) vs 68%
(43/63)
Direct sequencing
Korean  study [43] 63% (70/111g) T315I (24%)h
E255K (11%)h
G250E (10%)h
Y253H (10%)h
CP; AP; BP NA ASO-PCR and direct
sequencing
Polish  MAPTEST study [44] 12% (11/92i) T315I (27%)
M351T (18%)
F359V (18%)
CP; BP; AP 40% (2/5) vs 10%
(9/87)
Direct sequencing
Indian  study [45] 33% (25/76) T315I (16%)
M244V (16%)
Y253F/H (12%)
E255K (12%)
G250E (8%)
F311I (8%)
CP; AP; BP NA Direct sequencing
Hungarian  study [46] 36% (27/74j,k) M244V (19%)
T315I (15%)
M351T (15%)
E255V (11%)
F359I/V (7%)
CP; AP; BP; Ph+ALL NA Direct sequencing
French  study [47] NA T315I (19%)h
M244V (10%)h
M351T (10%)h
E255V/K (9%)h
CP; AP; BP NA Direct sequencing
Australian  study [48] l 19% (27/144) M351T (30%)
E255L (19%)
Q252H (19%)
E355G (11%)
CP; AP NA Direct sequencing
Australian  study [49] NA T315I (14%)
M351T (12%)
G250E (12%)
F359V (9%)
M244V (9%)
Y253H (8%)
CP; AP; LBC/Ph+ALL;
MBC
NA  Direct sequencing
CML, chronic myeloid leukemia; GIMEMA CML  WP,  Italian Group for Hematological Malignancies of the Adult CML  Working Party; CP, chronic phase; LBC/Ph+ALL, lymphoid
blast  crisis/Philadelphia chromosome positive acute lymphoblastic leukemia; MBC, myeloid blast crisis; AP, accelerated phase; D-HPLC, denaturing high-performance liquid
chromatography; NA, not applicable; ASO-PCR, allele-speciﬁc oligonucleotide-polymerase chain reaction.
a n is the number of patients with mutations and N is the number of patients in whom mutation analysis was performed.
b The percentage indicates the number of patients with a speciﬁc mutation divided by the total number of patients with mutations; the most frequent mutations are
reported.
c n is the number of patients with mutations and N is the number of patients who  showed clinical resistance (deﬁnition of resistance was different across these studies).
d 154 patients had received interferon- prior to imatinib.
e 69 patients had received interferon- prior to imatinib.
f 76 patients had received interferon- prior to imatinib.
g 25 patients had received interferon- prior to imatinib.
h The percentage indicates the number of a speciﬁc mutation divided by the total number of mutations.
i 18 patients had received hydroxyurea or interferon- alone or in combination with arabinoside cytosine prior to imatinib.
j 34 patients had received interferon- prior to imatinib.
k The frequency of BCR-ABL1 mutations in CML  patients only was  32% (22/69).
l Patients had received 6 or more months of imatinib therapy or had developed resistance and ceased therapy before 6 months.
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Table 3
Summary of mutation analysis conducted in a series of clinical trials of dasa-
tinib/nilotinib in the second-line setting.
Trial Frequency of
BCR-ABL1
mutations (n/N)a
Frequency of
mutations among
patients with
mutationsb
Dasatinib second-line
START-C, START-R, and
CA180-034 [25]
27% (47/174)c T315I (53%)
F317L (21%)
V299L (15%)
Nilotinib second-line
Phase II nilotinib registration
trial [23]
24% (47/192)d,e , f E255K/V (28%)
T315I (26%)
F359C/V (15%)
G250E (15%)
Y253H (13%)
Dasatinib/nilotinib second-line
MD  Anderson Cancer Center
[40]
21% (23/110):g
14% (8/56) for
dasatinib
28% (15/54) for
nilotinib
Y253H (13%)
F317L (13%)
T315I (9%)
V299L (9%)
F311I (9%)
Italian study [24] 33% (31/95)h T315I (36%)i
F317L (20%)i
E255V/K (11%)i
V299L (9%)i
Y253H (9%)i
a n is the number of patients with mutations and N is the number of patients in
whom mutation analysis was  performed.
b The percentage indicates the number of patients with a speciﬁc mutation
divided by the total number of patients with mutations; the most frequent mutations
are  reported.
c Mutation analysis was  performed at the time of progression or discontinuation.
d Only patients resistant to imatinib have been included.
e Mutation analysis was  performed during nilotinib therapy.
f Frequency of new BCR-ABL1 mutations in patients who  experienced pro-
gression: 25/64 (39%); most frequent mutations: E255K/V (28%), T315I (28%),
E459G/E459K (12%).
g Mutation analysis was  performed after treatment with a second TKI.
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wh Mutation analysis was  performed during treatment with a second TKI.
i Includes patients who  relapsed on dasatinib or nilotinib as second or third TKI.
hite blood cell count, or death from any cause [51]. Thirty per-
ent of CP-CML patients discontinued the nilotinib registration trial
AMN107A2101 as second-line treatment because of disease pro-
ression, although 70% of the patients discontinued for any reason,
t a follow-up of 48 months [52]. In this trial, disease progression
as deﬁned as hematologic or cytogenetic relapse, or transforma-
ion to AP or BP [53].
Mutation analyses performed in several studies indicate that
pproximately 14–33% of CML  patients treated with second-line
asatinib or nilotinib develop new BCR-ABL1 mutations (Table 3).
he most common mutations with dasatinib were T315I, F317L, and
299L (Table 3). The most common mutations with nilotinib were
255K/V, T315I, F359C/V, G250E, and Y253H (Table 3) [23–25,40].
.3. Resistance and mutations with second-line bosutinib
The registration trial of bosutinib was conducted in 288
matinib-resistant or imatinib-intolerant CP-CML patients [54].
mong imatinib-resistant patients, 23% (45/200) discontinued
ue to disease progression or unsatisfactory response; among
matinib-intolerant patients, 7% (6/88) discontinued due to disease
rogression or unsatisfactory response. BCR-ABL1 mutation status
t baseline was available for 115 patients, 65 (57%) of whom had
t least one mutation. The most common mutations were M351T
n = 7), F359V (n = 7), F317L (n = 4), L248V (n = 4), G250E (n = 3),
244V (n = 3), and T315I (n = 3). Similar rates of CHR or MCyR
ere observed between patients with and without mutations. In aearch 38 (2014) 10– 20
subanalysis of 118 patients who had received imatinib followed by
dasatinib and/or nilotinib, emerging mutations were observed in
nine patients (one had 2 emerging mutations): V299L (n = 4), L248V
(n = 2), T315I (n = 2), F359C (n = 1), and G250E (n = 1) [55].
2.4. Resistance and mutations with ponatinib
Ponatinib has shown preclinical and clinical activity against a
spectrum of mutants including T315I [56,57]. In a phase 1 study,
among 43 heavily pretreated CP-CML patients, 3 (7%) discontin-
ued because of disease progression; all 12 of the patients carrying
the T315I mutation at baseline remained in the study [56]. Nine of
the 12 patients (75%) who  had the T315I mutation achieved CCyR.
Ten of the 15 patients (67%) who  had other mutations at base-
line (M244V, G250E, F317L, M351T, F359C/I/V) achieved CCyR. Six
of the 13 patients (46%) with no mutation at baseline had CCyR.
Kaplan–Meier analysis estimated that 91% of the CP-CML patients
with the T315I mutation who  experienced MCyR would maintain
response at 1 year. No data on emerging mutations are available to
date.
2.5. Resistance and mutations with ﬁrst-line dasatinib or nilotinib
Based on the DASISION, S0325 (US Intergroup study of dasa-
tinib versus imatinib in the ﬁrst-line setting), and ENESTnd trials,
dasatinib and nilotinib ﬁrst-line are associated with fewer fail-
ures than imatinib ﬁrst-line [14–16,58]. In the 2-year follow-up
of the DASISION trial, 9% (22/258) of CP-CML patients discontin-
ued ﬁrst-line dasatinib because of disease progression or treatment
failure, compared with 11% (28/258) treated with imatinib [14].
In the S0325 study, 2% (2/123) of CP-CML patients discontinued
ﬁrst-line dasatinib because of disease progression or treatment
failure, compared with 7% (8/123) treated with imatinib [58]. In
the 2-year follow-up of the ENESTnd trial, 9% (26/282) and 3%
(9/281) of CP-CML patients discontinued ﬁrst-line nilotinib (300 mg
and 400 mg  bid arms, respectively) because of disease progres-
sion, treatment failure or suboptimal response, compared with
17% (48/283) treated with imatinib [16]. At the 3-year follow-up
of the ENESTnd trial, 10% (28/282) and 5% (15/281) of CP-CML
patients discontinued ﬁrst-line nilotinib (300 mg and 400 mg  bid
arms, respectively) because of disease progression, treatment fail-
ure or suboptimal response, compared with 20% (57/283) treated
with imatinib [15]. The deﬁnition of progression and the duration of
follow-up prior to censoring were not uniform among these stud-
ies.
In the DASISION trial, mutation analysis was performed at the
time of disease progression, treatment failure or end of treatment
[59]. The frequency of emerging mutations among patients who
discontinued treatment was similar between dasatinib-treated and
imatinib-treated patients. At the 2-year follow-up, 26% (10/38) of
patients treated with dasatinib who  had an evaluable mutation
analysis performed at discontinuation had a mutation compared
with 21% (10/48) of patients treated with imatinib [14]. There
were 6 cases of nonevaluable samples in the dasatinib group and
one case in the imatinib group. Treatment failure was  deﬁned
as disease progression, no hematologic response at 3 months, no
CHR or no CyR at 6 months, no PCyR at 12 months, or no CCyR
at 18 months [59]. Speciﬁcally, the 10 dasatinib-treated patients
carrying mutations had the following mutations: T315I (n = 7),
F317L (n = 2), and F317I/V299L (n = 1) [14]. In the US Intergroup
S0325 study, mutation analysis was  successfully conducted in 22
patients with evidence of resistant disease or with hematologic or
cytogenetic relapse or progression; 1 of 9 (11%) dasatinib-treated
patients and 2/13 (15%) of imatinib-treated patients had a mutation
[58].
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In the ENESTnd trial, mutation analysis was  performed in all
atients at baseline. In patients with no baseline mutations, muta-
ion analysis was performed when patients experienced either lack
f response or loss of response (deﬁned as failure to achieve MMR
t 12 months; conﬁrmed loss of MMR  during the study; or rise
n BCR-ABL1 transcript level by ≥5-fold from the lowest value
chieved on study), and at the end of study. In patients with base-
ine mutations, mutation analysis was performed every 3 months
60,61]. The frequency of emerging mutations during treatment
as lower in the nilotinib arms than in the imatinib arm of the
NESTnd trial. At the 3-year minimum follow-up, 5% (11/228)
nd 5% (11/215) of patients with at least one postbaseline muta-
ion analysis treated with nilotinib (300 mg  and 400 mg  bid arms,
espectively) had a mutation compared with 9% (21/237) treated
ith imatinib [60]. The 11 patients in the 300 mg  bid nilotinib
roup carrying new mutations (3 patients had multiple muta-
ions) had the following mutations: Y253H (n = 4), F359V (n = 4),
315I (n = 3), G250E (n = 1), E255K (n = 1), E459K (n = 1) [60]. The 11
atients in the 400 mg  bid nilotinib group carrying new mutations
2 patients had multiple mutations) had the following mutations:
253H (n = 4), E255K/V (n = 3/1), T315I (n = 2), F359V (n = 2), Q252H
n = 1).
. Prognostic implications of BCR-ABL1 KD mutations
.1. Imatinib
Emergence of new BCR-ABL1 KD mutations during imatinib
reatment predicts loss of CCyR, shorter progression-free survival
PFS), shorter time to AP/BP progression, and shorter overall sur-
ival (OS) during ﬁrst-line imatinib treatment [62–65].
In a series of 319 CP-CML patients treated with imatinib at
he Hammersmith Hospital and with mutation analysis avail-
ble, BCR-ABL1 KD mutations were identiﬁed in 37 patients (12%)
62]. Of these 319 patients, 171 patients received ﬁrst-line imat-
nib therapy. Thirty of 214 patients (14%) who achieved CCyR
ost their response during follow-up, and multivariate analy-
is revealed that emergence of BCR-ABL1 KD mutations was
ighly predictive of loss of CCyR (RR = 3.8; P = 0.005). Patients
ho had developed a mutation (n = 23) by 2 years of imatinib
reatment had a signiﬁcantly lower 5-year PFS compared with
hose who had not developed a mutation (n = 227; 65% vs 86%;
 = 0.0001).
In a series of 150 CP-CML patients treated with imatinib at
he Knight Cancer Institute (most of whom had received prior
reatment with interferon-), mutation screening was undertaken
n 101 patients in whom BCR-ABL1 RNA had increased at least
-fold during treatment [63]. Mutations were identiﬁed in 53
atients (52%). Median PFS was signiﬁcantly shorter (P < 0.001) for
atients with mutations (10.4 months) compared with those with-
ut mutations (32.4 months); with a hazard ratio of 3.2 (95% CI,
.9–5.4).
A retrospective molecular analysis was conducted on 40 late
P-CML patients intolerant or resistant to interferon- and with
ytogenetic resistance to imatinib, who were enrolled in the
ML/002/STI571 GIMEMA trial conducted before the advent of
asatinib and nilotinib [65]. All 40 patients failed to obtain MCyR
t 12 months, and mutations were found in 19 (48%). The pres-
nce of BCR-ABL1 KD mutations was associated with signiﬁcantly
horter time to AP/BP progression (P = 0.0002) and shorter survival
P = 0.001).
In a series of 40 CML  patients who were resistant to imatinib and
ntolerant or resistant to interferon-, mutations were found in 18
atients (45%) [64]. The 2-year PFS was signiﬁcantly inferior for
atients with mutations compared with those without mutations
72% vs 95%, P = 0.0045).search 38 (2014) 10– 20 15
3.2. Second-line dasatinib and nilotinib
Several studies found that CP-CML patients who  harbored
mutants less sensitive to dasatinib or nilotinib in vitro experienced
lower CCyR rates and PFS rates than patients harboring mutants
with high or unknown in vitro sensitivity to dasatinib or nilotinib
[23,25,66].
Patients with CP-CML treated with second-line dasatinib, who
participated in the trials START-C, START-R, and CA180-034, were
analyzed at 2-year follow-up [25]. Among 121 patients who had
a BCR-ABL1 mutant with an intermediate in vitro sensitivity to
dasatinib (IC50 >3 nM), 32% had CCyR and PFS was  67%. Among
patients who  had a mutant with a high in vitro sensitivity to dasa-
tinib (IC50 ≤ 3 nM,  n = 176) or unknown IC50 (n = 84), 53% and 51%
achieved CCyR, and the PFS rates were 75% and 80%, respectively.
Patients who participated in the phase 2 nilotinib second-line
registration trial were analyzed at the 1-year follow-up [23]. Among
26 patients who had a BCR-ABL1 mutant with an intermediate
in vitro sensitivity to nilotinib (IC50 > 150 nM), none achieved CCyR
and the PFS was 31%. Among patients who had a mutant with a high
in vitro sensitivity to nilotinib (IC50 ≤ 150 nM,  n = 45) or unknown
IC50 (n = 29), 40% and 48% achieved CCyR, and the PFS was  64% and
59%, respectively.
In a study conducted at the MD Anderson Cancer Center in 86
CML patients with baseline mutations (30 with CP-CML, 41 with
AP-CML, and 15 with BP-CML) treated with dasatinib or niloti-
nib after imatinib failure, response rates were lower in CP-CML
patients carrying intermediate IC50 mutations (25% for both MCyR
and CCyR), compared with those with low IC50 mutations (87% and
73%, respectively) [66]. The 2-year EFS rates were lower in CP-CML
patients carrying intermediate or high IC50 mutations (22% and
0%, respectively), compared with those with low or not reported
IC50 mutations (78% and 67%, respectively), as were the 2-year
OS rates (70% and 75%, respectively, for intermediate or high IC50
mutations), versus 100% for patients with low or not reported IC50
mutations.
3.3. T315I mutations
Prior to the availability of ponatinib, several studies have shown
that CML  patients harboring the T315I mutation have a poor prog-
nosis [47,49,67,68]. In a series of 386 imatinib-treated patients
with mutations, T315I mutations were more frequently detected
in patients who  had progressed to BP [49]. A retrospective analysis
from the French CML  intergroup conducted in 89 imatinib-resistant
CML  patients showed that across all phases of CML, median OS
was  12.6 months for the T315I mutation (n = 15), and not reached
for other mutations (n = 47; P < 0.000405) [47]. Patients with CP-
CML  and with T315I (n = 8) mutations had worse OS and PFS
than patients with other mutations (n = 38 and n = 37, respectively;
P = 0.014 for each). A retrospective observational study in 176 CML
patients carrying the T315I mutation who received ﬁrst- or second-
generation TKIs revealed that survival of patients harboring a T315I
mutation is dependent on the disease phase at the time of mutation
detection, with worse outcome for BP-CML patients [68]. Median
OS rates from the time of T315I detection were 22.4, 28.4, and 4.0
months for CP-, AP-, and BP-CML, respectively. In a matched paired
analysis, 64 CP-CML patients resistant to imatinib and carrying the
T315I mutation were compared with 53 CP-CML patients resistant
to imatinib with no detectable T315I mutation [67]. This study con-
ﬁrmed that the T315I mutation has a negative impact on OS and
failure-free survival (FFS). Median OS since imatinib resistance was
48 months in patients carrying the T315I mutation, while it was not
reached in patients without the T315I mutation (P = 0.006). Median
FFS since imatinib resistance was  35 months in patients carrying
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he T315I mutation, while it was not reached in patients without
he T315I mutation (P = 0.003).
.4. Low-level mutations
Low-level mutations are mutations that are below the detec-
ion limit of conventional direct sequencing and are detected only
ith more sensitive methods. The clinical signiﬁcance of low-level
utations in CML  patients has long been debated and remains, at
resent, unclear. Retrospective studies have suggested that muta-
ions found in rare Ph+ cells may  fail to expand and their detection
oes not consistently predict relapse [69,70]. One of these studies
as conducted in patients with stable CCyR to imatinib by direct
equencing and denaturing high-performance liquid chromatog-
aphy (D-HPLC) [69]; the other was conducted in imatinib-naïve
atients by allele-speciﬁc oligonucleotide-polymerase chain reac-
ion and direct sequencing [70].
In a mutation analysis conducted in 220 CML  patients at imatinib
ailure, before starting nilotinib or dasatinib therapy, 281 muta-
ions were detected in 131 patients by sensitive mass spectrometry
29]. Of these 281 mutations, 132 were not detected by sequenc-
ng. Mutants that were resistant to nilotinib and/or dasatinib were
etected in 32% of the patients by mass spectrometry, compared
ith 23% by sequencing. Therefore, mass spectrometry allowed
he detection of an additional 9% of patients who could beneﬁt
rom selecting the most appropriate therapy after imatinib fail-
re.
This study also showed that low-level nilotinib-/dasatinib-
esistant mutations are associated with poor response and high
isk of failure. Patients with low-level mutations resistant to nilot-
nib or dasatinib, detected upon imatinib failure, achieved low
CyR rates (16%) with nilotinib or dasatinib therapy, compared
ith patients with other mutations (41%) or patients with no
utations (49%). Patients with low-level resistant mutations had
xtremely poor failure-free survival at 18 months after therapy
ith nilotinib or dasatinib (0%), compared with 51% for patients
ith other low-level mutations and 45% for those with no muta-
ions.
The apparently contrasting results regarding the correlation of
ow-level mutations with subsequent relapse in the studies pre-
ented may  be due to the fact that different techniques were used
nd different patient populations were analyzed. It is possible that
 lower detection limit (to be identiﬁed) exists, below which muta-
ions may  not necessarily expand for biological or clinical reasons.
his hypothesis needs further studies.
.5. Multiple mutations
Studies have shown that patients with multiple mutations
ave a poorer prognosis than those with no or one mutation
28,71]. In a study conducted at the MD  Anderson Cancer Cen-
er, 7 of 207 imatinib-resistant CML  patients (3%) treated with a
econd-generation TKI (nilotinib, dasatinib, bosutinib, or the inves-
igational TKI bafetinib) had more than one mutation detected
y direct sequencing [71]. Of 102 CP-CML patients, 4 (4%) had
ultiple mutations. This study showed that patients with more
han one mutation have a signiﬁcantly worse outcome than those
ith no or one mutation. The 4-year PFS rates were 56% (no
utation), 49% (1 mutation), and 0% (more than 1 mutation;
 = 0.02).
In a study of 220 patients treated with nilotinib or dasatinib after
matinib resistance, mutation analysis was conducted by sequenc-
ng and by mass spectrometry [28,29]. By sequencing, multiple
utations were detected in 31 patients (14%) after imatinib failure,
ith one case with mutations clinically resistant to both niloti-
ib and dasatinib; by mass spectrometry, 60 patients (27%) hadearch 38 (2014) 10– 20
multiple mutations, with 5 cases with mutations known to confer
clinical resistance to both nilotinib and dasatinib [29]. In patients
without mutations clinically resistant to nilotinib or dasatinib, mul-
tiple sensitive mutations detectable only by mass spectrometry and
detected after failure of imatinib treatment were associated with
lower CCyR rates achieved after second-line TKI therapy, compared
with no mutation or one mutation (21% vs 50%, P = 0.003) [28].
3.6. Dasatinib and nilotinib ﬁrst-line
Based on the 2-year follow-up of the DASISION trial, the devel-
opment of BCR-ABL1 KD mutations may  predict progression to
advanced phase. Among the 10 dasatinib-treated patients who
developed a mutation, transformation to AP/BP occurred in 4
patients while among the 10 imatinib-treated patients who  devel-
oped a mutation, transformation to AP/BP occurred in 3 patients
[14].
Based on the 3-year follow-up of the ENESTnd trial, fewer
nilotinib-treated patients who developed mutations during treat-
ment had treatment failure, suboptimal response, or lost response
on treatment, than imatinib-treated patients who developed muta-
tions [60]. Among the 11 patients in the 300 mg  bid nilotinib
group who developed a mutation, 4 patients experienced treatment
failure, 6 patients had suboptimal response, and one patient pro-
gressed after discontinuation; among the 11 patients in the 400 mg
bid nilotinib group who developed a mutation, 6 patients expe-
rienced treatment failure, 2 patients had suboptimal response, 2
patients had conﬁrmed loss of MMR,  and one patient had an uncon-
ﬁrmed loss of MMR  but regained MMR  later; among the 21 patients
in the imatinib group who  developed a mutation, 16 patients expe-
rienced treatment failure and 5 patients had suboptimal response.
Three of 22 patients with mutations in the nilotinib arms had not
discontinued treatment at the 3-year follow-up. As mentioned pre-
viously, the trigger for mutation analysis in clinical studies has not
been uniform.
4. Guidelines
4.1. When to perform mutation analysis based on ELN, ESMO,
and NCCN recommendations
The ELN, European Society for Medical Oncology (ESMO), and
NCCN provide recommendations about when BCR-ABL1 KD muta-
tion analysis should be performed in CML  patients treated with
TKIs; these are summarized in Table 4 [3,22,72].
According to the ELN and the ESMO recommendations, mutation
analysis is recommended at diagnosis only in AP-/BP-CML patients,
before starting ﬁrst-line therapy [22,72]. However, in the absence
of prospective studies based on mutation screening up front and
the low rate of mutation detection, it is questionable whether this
is sensible or cost-effective. The NCCN recommends mutation anal-
ysis in TKI-pretreated AP-/BP-CML patients [3].
The ELN and the ESMO recommendations differentiate between
ﬁrst-line and second-line treatment, while the NCCN guidelines do
not differentiate across lines of treatment. According to the ELN
and the ESMO recommendations, BCR-ABL1 KD mutation analy-
sis should be performed during second-line treatment in case of
hematologic or cytogenetic failure, whereas based on the NCCN
guidelines, mutation analysis should also be performed in case of
loss of response, inadequate response, or increased BCR-ABL1 tran-
script levels.4.2. Mutation status aids therapeutic decisions
The results of the mutation analysis should guide the choice
of subsequent therapy, as per ELN and NCCN recommendations
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Table 4
Summary of recommendations for BCR-ABL1 KD mutation analysis.
At diagnosis During ﬁrst-line therapy with
imatinib
During second-line therapy with
dasatinib or nilotinib
ELN and ESMO
recommendations
• Only in patients with AP-/BP-CML
• In case of failure In case of hematologic or
cytogenetic failure, including:
•  In case of an increase in
BCR-ABL1 transcript levels
leading to a loss of MMR
• No CyR at 3 months
•  In case of suboptimal response • Minimal CyR at 6 months
•  Before changing to other TKIs or
other therapies
• Less than PCyR at 12 months
•  Before changing to other TKIs or
other therapies
NCCN  recommendations • In case of disease progression to AP or BP • In patients with CP-CML who have inadequate initial response,deﬁned as failure of achieving PCyR or BCR-ABL1/ABL1 ≤10% (on the
international scale) at 3 months or CCyR at 12 and 18 months
•  In patients with CP-CML at any sign of loss of response, deﬁned as
hematologic or cytogenetic relapse or 1-log increase in BCR-ABL1
transcript level and loss of MMR
E celerated phase; BP, blast phase; CML, chronic myeloid leukemia; MMR,  major molecular
r ic phase; NCCN, National Comprehensive Cancer Network; CCyR, complete cytogenetic
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Table 5
Summary of recommendations for most appropriate treatment options based on
BCR-ABL1 KD mutation status.
Mutations 2011 ELN recom-
mendations
[22]
2013 NCCN recom-
mendations
[3]
T315I • Ponatinib [10] • Ponatinib
(preferred)
•  Hematopoietic
stem cell
transplantation
• Omacetaxinea
• Clinical trials • Hematopoietic
stem cell
transplantation
•  Clinical trial
V299L • Nilotinib • Ponatinib
• Nilotinib
• Omacetaxinea
T315A • Ponatinib
• Nilotinib
• Imatinibb
• Bosutinib
• Omacetaxinea
F317L/V/I/C • Ponatinib
• Nilotinib
• Bosutinib
• Omacetaxinea
Y253H, E255K/V, or F359V/C/I • Dasatinib • Ponatinib
• Dasatinib
• Bosutinib
• Omacetaxinea
Any other mutation • High-dose
imatinib
• Ponatinib
• Dasatinib • High-dose
imatinibc
• Nilotinib • Dasatinib
• Nilotinib
• Bosutinib
• Omacetaxinea
ELN, European LeukemiaNet; NCCN, National Comprehensive Cancer Network.LN, European LeukemiaNet; ESMO, European Society for Medical Oncology; AP, ac
esponse; CyR, cytogenetic response; PCyR, partial cytogenetic response; CP, chron
esponse.
Table 5) [3,22]. ELN recommendations based on mutation analysis
ere published in 2011, before the approval of bosutinib, pona-
inib, and omacetaxine [22]. The 2013 ELN recommendations for
he management of CML  are speciﬁc only for the T3151 muta-
ion; the recommendations otherwise focus on the targeted desired
esponse, regardless of which TKI inhibitor is used [10].
. Future trends in detection of BCR-ABL1 mutations
.1. Current techniques for mutation analysis
Direct sequencing is currently the most extensively used tech-
ique to detect BCR-ABL1 mutations in clinical practice, and is
ecommended by ELN and ESMO [22,72]. Direct sequencing allows
etection of mutations present in ≥20% of Ph+ cells [22]. Dena-
uring high-performance liquid chromatography can be combined
ith direct sequencing; D-HPLC allows prescreening for sequence
ariations, reducing the number of samples to be sequenced [22]
nd improves the limit of detection to 1%, but alone does not allow
haracterization of the precise sequence [73]. Subcloning prior to
equencing is a well-established, relatively “old” and inexpensive
pproach capable of detecting compound mutations, but is very
abor intensive and highly prone to contamination and therefore
ot suitable for routine diagnostics [73]. Sensitive detection of
ow-level mutations after imatinib failure may  help to inform the
election of subsequent therapy, although this should be conﬁrmed
y independent studies.
.2. Newer technologies with higher sensitivity
Newer technologies to detect mutations at a higher sensitivity
re still experimental, not yet incorporated into clinical practice.
ome of these new technologies include mass spectrometry, digital
CR, and NGS (or ultra-deep sequencing).
Mass spectrometry is a very sensitive technique, with a detec-
ion limit ranging from 0.05% to 0.5% depending on the mutation
0.2% on average) [28,29]. It has been used to detect 31 speciﬁed
ost frequent and clinically relevant mutations, including all ofhe nilotinib- and/or dasatinib-resistant mutations and the most
ommon imatinib-resistant mutations (detected in ≥1% of patients
ith mutations) [28,29]. However, more mutations can be included
n the multiplex screening.
a Treatment option after resistance and/or intolerance to ≥2 TKIs.
b If mutation detected following dasatinib treatment.
c Sufﬁcient dose-escalation data not available to indicate if mutations with lower
IC50 values are sensitive to high-dose imatinib.
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The Fluidigm quantitative real-time digital PCR is a nanoﬂuidic-
ased method characterized by partitioning the sample into
housands of independent reaction chambers, increasing the detec-
ion of rare mutations [74]. This technology can assess the kinetics
f mutation development, allowing earlier detection of mutations
nd potentially allowing correlating kinetics of mutation develop-
ent with outcomes. It has been used to identify and quantify the
315I mutation in CML  patients. Samples from 28 patients taken
oth before and at the time of relapse were analyzed and the T315I
utation was detected before relapse in all 8 patients in whom it
as detected at relapse.
The unique advantage of NGS over other methods is conjugat-
ng high sensitivity with the detection of any (known/unknown)
utation within the KD of BCR-ABL1.  The Roche GS Junior system
tilizes emulsion PCR to densely decorate beads with mono-
lonal DNA templates followed by pyrosequencing [75]. The Ion
orrent system utilizes semiconductor technology to directly
etect hydrogen ions released during base incorporation allow-
ng sequencing-by-synthesis [76]. The Illumina system utilizes a
equencing-by-synthesis approach with a reversible terminator-
ased method to detect single bases as they are incorporated into
NA strands [77].
A BCR-ABL1 KD mutation screening approach has recently been
et established on the Roche GS Junior system and has proven reli-
bility and reproducibility to detect mutations with an abundance
s low as 1% [78]. In a retrospective analysis of patients who had
ailed multiple lines of TKI therapy, this technology showed that
he BCR-ABL1 mutation status as detected by conventional meth-
ds may  represent just the tip of the iceberg [78]. In 55% of the
amples, mutations undetectable by direct sequencing were found
y NGS. In addition, NGS revealed that samples harboring multiple
utations often represent a complex mosaic of clones with both
ompound and polyclonal mutations, indicating that these types
f mutations are not mutually exclusive. However, the GS Junior
hemistry can only allow reconstruction of clonal architecture only
f multiple mutations map  in a region < 450 bp. The recently devel-
ped Paciﬁc Biosciences system using Single Molecule Real-Time
SMRT®) circular consensus sequencing technology affords single-
olecule, real-time DNA synthesis and provides longer reads. This
liminates potential ampliﬁcation errors and allows the sequencing
ingle strands of DNA including the entire KD of BCR-ABL1.  SMRT®
echnology has been reported to have a detection sensitivity of less
han 0.1% [79].
. Conclusion
Based on the literature reviewed, a current unmet medical
eed in CML  treatment is the detection of evolving multidrug-
esistant compound mutations, which may  present formidable
hallenges for targeted agents. Although early clinical data from
andomized studies comparing nilotinib or dasatinib with imat-
nib in newly diagnosed CP-CML patients show superior activity
or second-generation TKIs, the failure rate is not zero; whether
he third-generation “pan-BCR-ABL1 inhibitor” ponatinib is capa-
le of further minimizing selection of drug-resistant mutants and
reventing the selection of compound mutations, and ultimately,
isease progression, remains to be seen. However, as our ability
o treat drug-resistant KD mutations improves, it will also become
ncreasingly important to gain better understanding of resistance
echanisms in the absence of KD mutations.ole of the funding source
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